158 related articles for article (PubMed ID: 38254153)
1. The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.
Li Y; Mao X; Li M; Li L; Tong X; Huang L
Clin Epigenetics; 2024 Jan; 16(1):16. PubMed ID: 38254153
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen.
Lai B; Mu Q; Zhang Y; Chen Y; Yan X; Ouyang G
Hematology; 2021 Dec; 26(1):751-757. PubMed ID: 34555298
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia.
He S; Li Y; Shi X; Wang L; Cai D; Zhou J; Yu L
Clin Epigenetics; 2023 Mar; 15(1):37. PubMed ID: 36864492
[TBL] [Abstract][Full Text] [Related]
4. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia.
He S; Li Y; Wang L; Li Y; Xu L; Cai D; Zhou J; Yu L
Neoplasia; 2024 Mar; 49():100965. PubMed ID: 38245923
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
[TBL] [Abstract][Full Text] [Related]
7. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
[TBL] [Abstract][Full Text] [Related]
8. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
10. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
[TBL] [Abstract][Full Text] [Related]
11. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Senapati J; Shoukier M; Garcia-Manero G; Wang X; Patel K; Kadia T; Ravandi F; Pemmaraju N; Ohanian M; Daver N; DiNardo C; Alvarado Y; Aldrich J; Borthakur G
Am J Hematol; 2022 May; 97(5):574-582. PubMed ID: 35150150
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.
Maiti A; DiNardo CD; Wang SA; Jorgensen J; Kadia TM; Daver NG; Short NJ; Yilmaz M; Pemmaraju N; Borthakur G; Bose P; Issa GC; Ferrajoli A; Jabbour EJ; Jain N; Garcia-Manero G; Ohanian M; Takahashi K; Montalban-Bravo G; Masarova L; Burger JA; Thompson PA; Verstovsek S; Sasaki K; Andreeff M; Rausch CR; Montalbano KS; Pierce S; Qiao W; Ning J; Kantarjian HM; Konopleva MY; Ravandi F
Blood Adv; 2021 Apr; 5(7):1876-1883. PubMed ID: 33792630
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia.
Santini V; Lübbert M; Wierzbowska A; Ossenkoppele GJ
Adv Ther; 2022 Apr; 39(4):1474-1488. PubMed ID: 34786648
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
18. Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy.
Hilberink JR; Morsink LM; van der Velden WJFM; Mulder AB; Hazenberg CLE; de Groot M; Choi G; Schuringa JJ; Meijer K; Blijlevens NMA; Ammatuna E; Huls G
Transplant Cell Ther; 2021 Mar; 27(3):246-252. PubMed ID: 33781523
[TBL] [Abstract][Full Text] [Related]
19. Decitabine Compared With Conventional Regimens in Older Patients With Acute Myeloid Leukemia: A Meta-Analysis.
Bian MR; Yang HS; Lin GQ; Wan Y; Wang L; Si YJ; Zhang XX; Wang M; Zhou H; Zhao GS; Zhang YM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):e636-e648. PubMed ID: 31645307
[TBL] [Abstract][Full Text] [Related]
20. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
[No Abstract] [Full Text] [Related]
[Next] [New Search]
